210353-53-0

Basic information

• Product Name: Gemifioxacin mesylate
• Synonyms: GEMIFIOXACIN MESYLATE;7-(3-aminomethyl)-4-methoxyimino-pyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]naphthyridine-3-carboxylic acid mesylate;LB-20304 Mesilate;Gemifioxacin mesylate, 98.5%
• CAS NO: 210353-53-0
• Molecular Formula: C19H24FN5O7S
• Molecular Weight: 485.49
• EINECS: 1312995-182-4
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals
• Mol File: 210353-53-0.mol

Chemical Properties

• Melting Point: 235-2370C
• Boiling Point: 638.9 °C at 760 mmHg
• Flash Point: 340.2 °C
• Appearance: beige solid
• Storage Temp.: -20°C Freezer
• Solubility: DMSO (Slightly), Methanol (Slightly, Heated), Water (Slightly)
• Stability: Hygroscopic
• CAS DataBase Reference: Gemifioxacin mesylate(CAS DataBase Reference)
• NIST Chemistry Reference: Gemifioxacin mesylate(210353-53-0)
• EPA Substance Registry System: Gemifioxacin mesylate(210353-53-0)

Safety Data

• Safety Statements: 24/25
• Hazardous Substances Data: 210353-53-0(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
Gemifloxacin mesylate is used as an antimicrobial agent for the treatment of bacterial respiratory infections. It is particularly effective against Streptococcus pneumoniae, including isolates resistant to b-lactams, macrolides, and ciprofloxacin. It is specifically indicated for treating community-acquired pneumonia (CAP) caused by multi-drug resistant S. pneumoniae and for treating acute bacterial exacerbations of chronic bronchitis (AECB).
Used in Respiratory Infections Treatment:
Gemifloxacin mesylate is used as an oral treatment for bacterial respiratory infections, providing enhanced in vitro activity against various strains of bacteria. The recommended dose of gemifloxacin is 320 mg daily for 5 days for AECB and 320 mg daily for 7 days for CAP.
Used in Drug Resistance Management:
Gemifloxacin mesylate is used as a treatment option for multi-drug resistant S. pneumoniae, helping to manage and combat drug resistance in bacterial infections.

Originator

LG Life Sciences (S. Korea)

Biochem/physiol Actions

Gemifloxacin is a broad-spectrum quinolone antibacterial. Fluoroquinolones stabilize DNA strand breaks created by DNA gyrase and topoisomerase IV by binding to the enzyme-DNA complex generating persistent, covalent enzyme–DNA adducts, inhibiting DNA synthesis. Gemifloxacin is used in the treatment of acute bacterial exacerbation of chronic bronchitis and mild-to-moderate pneumonia. Gemifloxacin has also been found to inhibit migration and invasion of human colon cancer cells.

Upstream product

• 75-75-2 methanesulfonic acid 
• 175463-14-6 gemifloxacin 
• 329322-84-1 7-(3-aminomethyl-4-methoxyimino-pyrrolidine-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-[1,8]-naphthyridine-3-carboxylic acid 

Relevant articles and documents

NOVEL POLYMORPHS OF GEMIFLOXACIN MESYLATE

The present invention provides novel crystalline sesquihydrate form 1, sesquihydrate form 2, anhydrous form 3 and anhydrous form 4 of gemifloxacin mesylate, processes for their preparation and pharmaceutical compositions containing them. The present inven

AN IMPROVED PROCESS FOR THE PREPARATION OF GEMIFLOXACIN MESYLATE

The present invention relates to an improved process for the preparation of Gemifloxacin mesylate of formula (V). The present invention further provides novel intermediates of formula (II) and (IV), which are useful intermediates for the preparation of Gemifloxacin mesylate of formula (V) wherein R1 is linear or branched chain alkyl group having 1-3 carbon atoms.

Process for the production of a naphthyridine carboxylic acid derivative (methanesulfonate sesquihydrate)

A process for the production of a naphthyridine carboxylic acid derivative having antibacterial activity.

NEW PROCESS FOR PREPARING 4-AMINOMETHYL-3-ALKOXYIMINOPYRROLIDINE METHANESULFONATE

The present invention relates to a process for the preparation of 4-aminomethyl-3-alkoxyiminopyrrolidine methanesulfonate, a key intermediate of quinolone antibiotics. According to the process of the present invention, the total number of steps has been shortened to 2-3 steps, the solid separation is not required, and the use of costly chemicals, particularly (BOC)2O (t-butoxycarbonyl anhydride), several organic solvents and reactants, is eliminated.

Intermediates for the production of quinolone carboxylic acid derivatives

Chemical intermediates which are of use in the production of quinolone carboxylic acid derivatives having antibacterial activity.

PROCESS FOR PREPARING ACID SALTS OF GEMIFLOXACIN

The present invention relates to a process for preparing acid salts of Gemifloxacin, a quinolone type antibiotic agent having potent antimicrobial activity. The process according to the present invention can provide advantages such as simplicity of proces

Salt of naphthyridine carboxylic acid derivative

7-(3 -Aminomethyl-4-methoxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid methanesulfonate and hydrates thereof, processes for their preparation, pharmaceutical compositions comprising them, and their use in antibacterial therapy.

7-(4-aminomethyl-3-methyloxyiminopyrroplidin-1-yl)-1-cyclopropyl-6-flu oro-4-oxo-1,4-dihydro-1,8-naphthyridine-3-carboxylic acid and the process for the preparation thereof

The present invention relates to a novel quinolone compound having an excellent antibacterial activity. More specifically, the present invention relates to 7-(4-aminomethyl-3-methyloxyiminopyrrolidin-1-yl)-1-cyclopropyl-6-fluoro-4-oxo-1, 4-dihydro-1,8-nap